Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis

Archives of Dermatology

Volumn 146, Issue 2, 2010, Pages 127-132

  Lecluse, Lidian L A ^a   Driessen, Rieke J B ^d   Spuls, Phyllis I ^a   De Jong, Elke M G J ^d   Stapel, Steven O ^a   Van Doorn, Martijn B A ^b   Bos, Jan D ^a   Wolbink, Gert Jan ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JAN VAN BREEMEN INSTITUTE   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBODY; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PSORALEN;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS VULGARIS; REIMBURSEMENT; SCREENING TEST; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 76749092658     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.347     Document Type: Article

References (11)

1. Bartelds GM, Wolbink GJ, Stapel S, et al. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis. 2006;65(9):1249-1250.
2. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921-926.
3. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008;28(9):1122-1126.
4. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(3):711-715.
5. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006; 55(4):598-606.
6. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008; 58(1):106-115.
7. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;141(2):185-191.
8. Lecluse LL, Naldi L, Stern RS, Spuls PI. National registries of systemic treatment for psoriasis and the European "Psonet" Initiative. Dermatology. 2009; 218(4):347-356.
9. van der Laken CJ, Voskuyl AE, Roos JC, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):253-256.
10. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009;21(3): 211-215.
11. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552-1563.